Lupin Laboratories (Lupin) and Dr. Reddy’s Laboratories (DRL) both have plans for aggressive forays into the global arena. While the former is planning to target the cefotexamine market in the USA, the later is stepping on the gas by setting up joint ventures in China and Brazil.
DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro–intestinal), ciprolet (anti–infective) Nise (pain and fever), Enam (cardiovascular) etc.
Lupin is a world leader in anti–TB drugs. It holds 70–75% of the world market of a major anti–TB drug ethambutol. Nearly 48% of the company’s turnover is contributed by anti–TB drugs.
So far Hoechst Marion Roussel (HMR) has a dominant market share of around $ 120 m in the cefotexamine market in the US and holds the process patent. Normally the originator (i.e. the first company) allows a second entrant a 20% market share without getting into a price war. If this were to happen in the current case, Lupin can target a market of $ 24 m (Rs 1056 m) without risking retaliation from HMR.
This would help the company to diversify its product portfolio and also provide it with cash for venturing into newer and more lucrative products such as those relating to the cardiovascular where the company has a miniscule presence.
DRL on the other hand already has a well–established export business in the CIS countries. However, the Russian crisis last year caused a lot of bad debts for the company. The company wrote off around Rs 250 m over a period of two year’s. The Chinese market is a relatively closed market, hence the need for a joint venture with a Chinese company.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407